immatics starts RCC vaccine IMPRINT Phase III trial
The trial willo involve around 330 patients throughout the US and Europe. The trial intends to show the overall survival benefit of IMA901 in conjunction with standard first-line
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.